COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Risk Factors for Thrombosis in Immune Thrombocytopenia (RiFT-ITP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03820960
Recruitment Status : Recruiting
First Posted : January 29, 2019
Last Update Posted : July 30, 2020
Information provided by (Responsible Party):
University Hospital, Toulouse

Brief Summary:

Immune thrombocytopenia (ITP) is a rare autoimmune disease (annual incidence: 3-4/105 inhabitants) leading to an increased risk of spontaneous bleeding. ITP is said "primary" when not associated to other systemic disease (lymphoma, systemic autoimmune disease, chronic infectious disease…). First-line treatment is based on corticosteroids. Intravenous immunoglobulin (IVIg) is added in case of serious bleeding. In about 70% of adult cases, ITP becomes persistent or chronic (lasting >3 months and >12 months, respectively). Second-line treatments are then indicated. Among them, thrombopoietin-receptor agonists (TPO-RAs), romiplostim and eltrombopag are increasingly used. Splenectomy is used as ultimate treatment.

Paradoxically, the risk of thrombosis is higher in ITP patients in comparison with the general population, due to the release of young hyperactive platelets from bone marrow. The incidence of thrombosis in ITP patients has been estimated between 0.5 and 3/100 patients-years. However, risk factors for thrombosis in ITP are not known, except splenectomy that is used in very few patients now. The role of other ITP treatments in thrombosis occurrence has been evoked, particularly for corticosteroids and IVIg. TPO-RAs have been associated with a risk of thrombosis in clinical trials and pharmacovigilance studies, even in case of low or normal platelet count. However, this risk has not been measured in the real-life practice, adjusted for other risk factors for thrombosis.

Condition or disease
Immune Thrombocytopenia

Layout table for study information
Study Type : Observational
Estimated Enrollment : 700 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Risk Factors for Thrombosis in Immune Thrombocytopenia
Actual Study Start Date : February 1, 2019
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : March 2021

Primary Outcome Measures :
  1. Risk for thrombosis in adult primary ITP patients treated with ITP treatment [ Time Frame: from July 2009 until June 2015 ]
    Number of first hospitalization for arterial and veinous thrombosis in patients treated with ITP treatment

Secondary Outcome Measures :
  1. Risk thrombosis in adult primary ITP patients treated with TPO-RAs. [ Time Frame: from July 2009 until June 2015 ]
    Number of first hospitalization for arterial and veinous thrombosis in patients treated with ITP patients treated with TPO-RAs.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Observational population-based study in France in the French Adult Immune THrombocytopenia (FAITH) cohort from July 2009 until June 2015. The FAITH study identifies since July 2009 all incident primary ITP adults in France within the national health insurance database (Système National d'Informations Inter-Régimes de l'Assurance Maladie, SNIIRAM, >66 million inhabitants).

Inclusion Criteria:

  • Incident primary ITP adults

Exclusion Criteria:

  • Secondary as well as prevalent ITP patients on July, 30th 2009 are excluded by the algorithm

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03820960

Layout table for location contacts
Contact: Guillaume Moulis, MD 5 61 77 58 94 ext 33

Layout table for location information
University Hospital Toulouse Recruiting
Toulouse, France
Contact: Guillaume Moulis, MD         
Sponsors and Collaborators
University Hospital, Toulouse
Layout table for investigator information
Principal Investigator: Guillaume Moulis, MD University Hospital, Toulouse
Layout table for additonal information
Responsible Party: University Hospital, Toulouse Identifier: NCT03820960    
Other Study ID Numbers: RC31/17/0148
First Posted: January 29, 2019    Key Record Dates
Last Update Posted: July 30, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Toulouse:
Additional relevant MeSH terms:
Layout table for MeSH terms
Purpura, Thrombocytopenic, Idiopathic
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Blood Platelet Disorders
Hematologic Diseases
Purpura, Thrombocytopenic
Blood Coagulation Disorders
Thrombotic Microangiopathies
Hemorrhagic Disorders
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Skin Manifestations